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pain control in total hip and knee replacement:
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short- and long-term effectiveness
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Background: Surgical pain is managed with multi-modal anaesthesia in total hip replacement (THR) and total knee
replacement (TKR). It is unclear whether including local anaesthetic infiltration before wound closure provides additional
pain control.
Methods: We performed a systematic review of randomised controlled trials of local anaesthetic infiltration in patients
receiving THR or TKR. We searched MEDLINE, Embase and Cochrane CENTRAL to December 2012. Two reviewers
screened abstracts, extracted data, and contacted authors for unpublished outcomes and data. Outcomes collected
were post-operative pain at rest and during activity after 24 and 48 hours, opioid requirement, mobilisation, hospital stay
and complications. When feasible, we estimated pooled treatment effects using random effects meta-analyses.
Results: In 13 studies including 909 patients undergoing THR, patients receiving local anaesthetic infiltration
experienced a greater reduction in pain at 24 hours at rest by standardised mean difference (SMD) −0.61
(95% CI −1.05, −0.16; p = 0.008) and by SMD −0.43 (95% CI −0.78 −0.09; p = 0.014) at 48 hours during activity.
In TKR, diverse multi-modal regimens were reported. In 23 studies including 1439 patients undergoing TKR,
local anaesthetic infiltration reduced pain on average by SMD −0.40 (95% CI −0.58, −0.22; p < 0.001) at 24 hours
at rest and by SMD −0.27 (95% CI −0.50, −0.05; p = 0.018) at 48 hours during activity, compared with patients
receiving no infiltration or placebo. There was evidence of a larger reduction in studies delivering additional
local anaesthetic after wound closure. There was no evidence of pain control additional to that provided by
femoral nerve block.
Patients receiving local anaesthetic infiltration spent on average an estimated 0.83 (95% CI 1.54, 0.12; p = 0.022) and
0.87 (95% CI 1.62, 0.11; p = 0.025) fewer days in hospital after THR and TKR respectively, had reduced opioid
consumption, earlier mobilisation, and lower incidence of vomiting.
Few studies reported long-term outcomes.
Conclusions: Local anaesthetic infiltration is effective in reducing short-term pain and hospital stay in patients
receiving THR and TKR. Studies should assess whether local anaesthetic infiltration can prevent long-term pain.
Enhanced pain control with additional analgesia through a catheter should be weighed against a possible infection
risk.
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Total hip replacement (THR) and total knee replace-
ment (TKR) are widely used to treat diseased and dam-
aged joints. In 2012 there were 75,366 primary THR and
76,497 primary TKR procedures recorded in the Na-
tional Joint Registry for England, Wales and Northern
Ireland [1]. In the USA in 2010, the estimated numbers
of THR and TKR procedures performed were 332,000
and 719,000, respectively [2].
Pain is the primary indication for THR and TKR and
many preparatory, surgical and rehabilitation strategies
target reduction in pain. However, both short- and long-
term pain after THR and TKR are common [3-5]. Peri-
operative pain is managed with multi-modal analgesia
with additive or synergistic effects [6]. Regimens aim to
achieve good pain relief immediately after surgery while
allowing for early mobilisation and hospital discharge.
Other methods such as spinal and epidural anaesthetics
and the use of opioids may preclude early mobilisation
and rehabilitation [7,8].
Pain management by infusion of local anaesthetic into
wounds has been evaluated in diverse surgical proce-
dures. In their systematic review, Liu and colleagues
noted improved pain, reduced opioid use and side ef-
fects, increased patient satisfaction, and shorter hospital
stay in patients receiving local anaesthetic infiltration
[9]. Only one study included patients with THR or TKR
[10], but further evaluations have been reported [11].
More recent meta-analyses in abdominal surgery [12],
and lumbar spine surgery [13], have questioned the clin-
ical value of local anaesthetic wound infiltration.
Using systematic review methods and meta-analysis, our
objective was to synthesise evidence from randomised
controlled trials (RCTs) evaluating the effectiveness of
peri-operative local anaesthetic infiltration for pain control
in patients with THR and TKR. Pain outcomes were con-
sidered along with post-operative opioid requirement, mo-
bilisation, hospital stay and complications.
Methods
We identified RCTs using methods described in the
Cochrane handbook of systematic reviews of interventions
[14]. The review was conducted in accordance with PRISMA
guidelines [15] and a checklist is included as Additional
file 1. This review builds on a previous literature review,
without a further formal protocol published [11].
Search strategy and selection criteria
We searched MEDLINE and Embase on OvidSP and
Cochrane CENTRAL to 11th December 2012. The search
strategy covered RCTs, anaesthesia and analgesia, and
THR and TKR terms (Table 1). We tracked citations of
key articles in ISI Web of Science [10,16-19], and checked
reference lists. Two reviewers scanned abstracts and titles,acquired potentially relevant articles, and decided on in-
clusion based on pre-specified criteria, with disputes re-
solved by other authors.
We included RCTs of patients with primary unilateral
THR or TKR receiving local anaesthetic infiltration be-
fore wound closure compared with patients receiving no
local anaesthetic infiltration or placebo. We also in-
cluded studies comparing local anaesthetic infiltration
with other forms of analgesia and studies with additional
post-wound closure delivery of analgesics through cathe-
ters and injections. We excluded studies with interven-
tions exclusively after wound closure and studies in
patients receiving hip hemiarthroplasty or unicompart-
mental TKR. No language restrictions were applied and
translations were made by colleagues as required.
Data collection and extraction
Articles and inclusion/exclusion decisions were catalo-
gued in Endnote X5. Data were extracted on to piloted
forms and an Excel spreadsheet in duplicate. Authors
were contacted for unpublished outcomes and missing
data.
Information was extracted on study characteristics;
participant characteristics; anaesthesia procedures com-
mon to randomised groups; intervention (content of infil-
trate, timing and volume); additional intervention group
treatments; and control group treatment including pla-
cebo and alternative analgesia regimens.
Outcomes
Outcomes studied were pain at rest or during activity at
24 and 48 hours after surgery, opioid consumption, mo-
bilisation, length of hospital stay in days, and long-term
pain and function. Serious complications recorded were
altered state of consciousness, cardiovascular complica-
tions requiring treatment, central nervous system tox-
icity, dysarthria, dyspnoea, major surgical complications,
pneumonia, pulmonary embolism, respiratory depres-
sion, seizures, and swollen knee; or complications relat-
ing to deep infection. Adverse events were vomiting and
nausea.
Study quality
Potential sources of bias were recorded in a Cochrane
risk of bias table [14]. We considered random sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blind outcome assessment, incom-
plete outcome data, selective reporting, and other
sources of bias. We classified overall quality as low, un-
clear or high risk of bias.
Meta-analysis
We conducted meta-analyses for pain at rest and during
activity at 24 and 48 hours, length of hospital stay, and
Table 1 Search strategy as applied in MEDLINE
1 Anesthetics, Local/or local anaesthetic.mp.
2 Anesthetics, Local/or Anesthesia, Local/or Local anaesthesia.mp.
3 Anesthetics/or Anesthesia/or anaesthesia.mp. or Anesthetics, Local/or Anesthesia, Local/
4 anesthesia.mp.
5 anaesthetic.mp.
6 amides.mp. or Amides/
7 (“Huneke neural therapy” or “Neural therapy of Huneke” or benzocaine or bensokain or “Aminobenzoic Acid” or “Aminobenzoate” or bupivacain*
or buvacaina or sensorcaine or marcain* or svedocain* or levobupivacaine or carticain* or articain* or dibucaine or cinchocaine or Cincain or
Nupercain* or Sovcaine or etidocaine or duranest or “W19053” or “W 19053” or “W-19053” or Lidocaine or Lignocaine or Octocaine or Xylesthesin
or Xylocaine or Dalcaine or Xylocitin or Xyloneural or Mepivacain* or Carbocaine or Polocaine or isocaine or isogaine or Scandicain* or prilocaine
or Propitocaine or Tetracaine or Tetrakain or Amethocaine or Dicaine or Pantocaine or Pontocaine or Trimecaine or Mesocaine or ropivacaine).mp.
[mp = title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary
concept, unique identifier]
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 (incision or port* or (surg* and wound)).mp. [mp = title, abstract, original title, name of substance word, subject heading word, protocol









18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19 Arthroplasty, Replacement, Knee/or Arthroplasty, Replacement, Hip/
20 exp Arthroplasty, Replacement, Hip/or exp Hip Prosthesis/ or hip replacement.mp.
21 exp Arthroplasty, Replacement, Knee/or exp Knee Prosthesis/or knee replacement.mp.
22 knee prosthesis.mp. or exp Knee Prosthesis/
23 hip prosthesis.mp. or exp Hip Prosthesis/
24 total hip.tw.
25 total knee.tw.
26 Orthopedic Procedures/ or orthopaedic surgery.mp.
27 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28 8 and 18 and 27
*Ovid truncation character.
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pain and function outcomes were not suitable for meta-
analyses and results were summarised using a descriptive
narrative.
Follow-up times were approximated to the closest tim-
ing. When not specified, we assumed measurements
were taken at rest. Analyses were carried out in Stata 12
and Review Manager 5 and results are reported with
95% confidence intervals. Funnel plots were inspected to
assess small study effects [20]. Given the number of po-
tential effect modifiers, we used random effects models
for all meta-analyses.In meta-analysis, means and standard deviations of con-
tinuous variables such as pain intensity are required for
intervention and control groups. Pain outcomes are some-
times reported as medians and inter-quartile ranges due to
the recognised ceiling effects of pain measures after suc-
cessful pain management. However this is less of an issue
during early recovery. Kerr and Kohan presented distribu-
tions of pain intensity scores at rest and during walking on
the first and second day after THR or TKR [19]. The pro-
portion of people reporting no pain, and thus reflecting a
ceiling effect, ranged from 2 to 35% on days one and two
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Figure 1 Wound infiltration anaesthesia regimens for interventions
and comparators (controls).
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and standard deviations from medians and inter-quartile
ranges [14]. If no measures of variability were available
in articles, we contacted authors to obtain standard devi-
ations. If unavailable we used the method described by
Walter and Yao to estimate standard deviations from
ranges [21], or imputed values from the average across
studies with the same outcome.
As pain scores are reported on different scales we used
the standardised mean difference (SMD) as our measure
of treatment effect in meta-analyses [22]. To help in the
interpretation of the pooled estimates, we multiplied
SMD values by the mean standard deviation on the widely
reported 100 point VAS scale for the outcome. As the use
of this method is entirely dependent on the chosen
“typical” value [23], we used a mean standard deviation
calculated from all studies reporting the outcome [14].
For length of hospital stay, we compared means and
medians in studies reporting both, and examined indi-
vidual level data provided by some authors. Distributions
were right-skewed and followed a lognormal distribu-
tion. Some studies reported means and standard devia-
tions directly. For studies that reported medians and
inter-quartile ranges, or ranges, we estimated means and
standard deviations on the log scale and then back-
transformed them to the natural (unlogged) scale [24].
We reported the mean difference (MD) in days as our
measure of treatment effect in meta-analyses. Complica-
tions were compared between randomised groups using
meta-analysis with summary statistics calculated as the
Peto odds ratio (OR), the method of choice when event
rates are low [14,25].Analgesia regimen comparisons
Not all studies compared a local anaesthetic infiltration
intervention with no intervention or placebo. Thus
meta-analyses are reported separately for different regi-
men comparisons, which we label A-E. These are sum-
marised in Figure 1.
THR studies were grouped into comparisons A and B;
we and also report the combined comparison (A + B).
For TKR studies, we initially report results from a com-
bined meta-analysis across the first two subgroups (A + B),
comparing local anaesthetic infiltration with or without
further post-closure intervention against control. Further
analyses report the comparisons C, D and E.Heterogeneity and subgroup analyses
We quantified the differences in treatment effects between
groups using meta-regression. Heterogeneity within meta-
analyses was quantified using the τ2 and I2 statistics [26].
Sensitivity and sub-group analyses explored risk of bias in
the study, use of additional analgesia delivered through acatheter or injection, and inclusion of non-steroidal in-
flammatory agents or steroids in the infiltrate.
Results
Searches identified 839 articles of which 33 described 36
RCTs evaluating local anaesthetic infiltration in THR or
TKR. The flow diagram in Figure 2 summarises review
progress. Some consistency in outcome reporting was
apparent for pain outcomes but for opioid consumption
and ambulation the variety of outcomes precluded meta-
analysis.
Small study effects
Inspection of funnel plots for each meta-analysis gave
no strong indication of publication bias or small study
effects, but numbers of studies in individual analysis
groups were small such that it was difficult to assess
asymmetry.
Total hip replacement
Details of 13 studies including 909 patients with THR
[16,27-37], or a large majority with THR [10], are sum-
marised in Table 2 which also includes our summary risk
of bias assessment. A more detailed assessment of risk
of bias is included in Additional file 2. The mean num-
ber of patients randomised was 70 (range 37–120). We
assessed that 10 studies were at low risk of bias while
three studies had unclear risk of bias due to uncertainty
about blinding of outcome assessments.
Records identified through database 
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Figure 2 Systematic review flow diagram.
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Results of meta-analyses including up to 12 studies
[10,16,27-29,31-37], are summarised in Table 3 and Figure 3.
In patients receiving local anaesthetic infiltration (A and B),
there was strong evidence that pain was lower: at rest at
24 hours by SMD −0.61 (95% CI −1.05, −0.16; p = 0.008),
and during activity by SMD −0.85 (95% CI −1.45, −0.25; p =
0.006). This reflected reduced pain at 24 hours at rest by an
average of 12 points (95% CI 3, 21; p = 0.008), and during
activity by 24 points (95% CI 7, 42; p = 0.006) on a 100 point
scale. Average effect sizes at 48 hours were smaller for pain
at rest, SMD −0.29 (95% CI −0.52, −0.05; p = 0.018) and dur-
ing activity, SMD −0.43 (95% CI −0.78, −0.09; p = 0.014),
corresponding to 5 and 10 points on a 100 point scale,
respectively.
In seven studies with no additional post-closure analgesia
through a catheter or injection (A), patients receiving localanaesthetic infiltration reported lower pain at 24 hours at
rest by SMD −0.63 (95% CI −1.21, −0.06; p = 0.031),
equivalent to an average of 12 points lower pain. How-
ever, there was no strong evidence that the intervention
had an effect during activity or at 48 hours.
In five studies where patients received further post-closure
analgesia (B), pain was reduced on average at 24 hours dur-
ing activity by SMD −1.38 (95% CI −2.5, −0.26; p = 0.016),
equivalent to a 40 point decrease on a 100 point scale. Pain
at 48 hours was reduced, on average, at rest by SMD −0.49
(95% CI, −0.96, −0.02; p = 0.043) and during activity by
SMD −0.6 (95% CI −1.16, −0.04; p = 0.036) equivalent to 8
and 14 point decreases, respectively.
In one study, control patients received an epidural an-
algesia infusion [16]. Pain was lower for the duration of
the epidural infusion, but at 48 hours pain was higher in
the control group compared with the local anaesthetic
Table 2 Randomised controlled trials of local anaesthetic infiltration in total knee and hip replacement
Study country date Inclusion patients
(intervention: control)
Common treatment Latest post-surgical follow up Outcomes
Losses to follow up (intervention/ control)
Risk of bias summary
Intervention treatment (infiltrate volume)
Further treatment (if given)
Control
TOTAL HIP REPLACEMENT STUDIES
Aguirre et al. 2012 [34]
Switzerland Not specified
THR (minimally invasive) N = 76
(38:38) 58:58 years 53:50%
female
Spinal anaesthesia, PCA morphine 48 hours and to 3 months Intra-venous morphine
consumption, VAS pain at rest and with motion,
electrocardiogram, skin inflammation or infection,
satisfaction. 4 (2:2) lost to follow up, 3/4 caused
by catheter dislocation Low risk of bias
20 ml solution containing 60 mg ropivacaine
injected into wound before closure. Further
continuous infusion through catheter
20 ml placebo injection of saline.
Continuous infusion of saline
through catheter
Andersen KV et al. 2007 [16]
Denmark 2005–2006
THR, OA, elective N = 80 (40:40)
62:61 years 90:85% female
Spinal, post-operative oral oxycodon
hydrochloride as required
96 hours VAS pain, length of stay, time to
mobilisation, side effects and complications,
motor block (Bromage scale) 5 (2:3) patients
lost to follow up Unclear (blinding of
outcome assessment)
101.5 ml solution containing 200 mg
ropivacaine, 30 mg ketoralac and 0.5 mg
epinephrine infiltrated during surgery.
Further infiltrate through catheter
intra-articularly 8 hours after surgery.
Epidural infusion of ropivacaine
and morphine
Andersen LJ et al. 2007 [27]
Denmark Date not specified
THR, OA, uncemented, >80 years
N = 37 (19:18) 62:64 years 84:56%
female
Spinal anaesthesia, self-administered oral
oxycodone as rescue medication
6 weeks VAS pain at rest and on leg raise up to
8 hours, WOMAC pain to day 4, WOMAC pain,
stiffness and function after 1,2,4,6 weeks, EQ5D at
6 weeks, patient controlled analgesic use to
discharge, adverse events 3 patients out of 10
not fitting inclusion criteria were identified
retrospectively. No losses to follow up Low risk
of bias
151.5 ml saline solution containing 300 mg
ropivacaine, 30 mg ketorolac, and 0.5 mg
adrenaline infiltrated during surgery Further
infusion through catheter on day 1.
Saline placebo infiltration Saline
placebo infused through
catheter on day 1
Bianconi et al. 2003 [10] Italy
Date not specified
THR and TKR (78% THR), elective
N = 37 (18:19) 66:64 years 79:83%
female
Spinal anaesthesia. Loading dose of intravenous
morphine at end of surgery
72 hours VAS pain at 2,4,8,12,24,48,72 hours,
opioid consumption (rescue medication),
adverse events, length of hospital stay, patient
satisfaction No losses to follow up Low risk
of bias
40 ml saline containing 200 mg ropivacaine
infiltrated at end of surgery. Further ropivacaine
infusion through catheter for 55 hours after
closure. Intravenous saline infusion for 24 h
after surgery.
No placebo infiltration during
surgery. Saline infusion through
catheter for 55 h after closure.
Intravenous morphine plus
ketorolac infusion for 24 h.
Busch et al. 2010 [30] UK
2003–2005
THR, OA, age <80 years N = 64
(32:32) 61:65 years 50:54%
female
General or spinal anaesthesia, PCA morphine 2 years VAS at rest and activity, morphine
consumption (PCA), VAS satisfaction,
complications, Harris Hip Score, WOMAC,
length of hospital stay No losses to follow
up Low risk of bias
100 ml saline solution containing 400 mg
ropivacaine, 30 mg ketorolac, 5 mg epimorphine,
and 0.6 ml epinephrine (1:1000) infiltrated during
surgery.
No placebo infiltration
Dobie et al. 2012 [35] UK
2006–2007
THR, OA or RA N = 96 (50:46)
67:67 years 38: 52% female
Spinal, general, intravenous morphine after
surgery as required.
6 days VAS at 24 h, morphine consumption,
walking and stair test, mobilisation velocity
and day, sit to stand test, home readiness,
hospital stay, Iowa Level of Assistance Scale
4 (4:0) patients did not receive intervention as
planned. Intention to treat results. Some data
missing for 1 control Low risk of bias
160 ml saline solution containing 200 mg
levobupivacaine and adrenaline
No local infiltration




THR, 13% OA, 72% Osteonecrosis
N = 60 (30:30) 51:55 years 37:43%
female
General anaesthesia 5 days VAS pain, ambulation, doses of
parenteral analgesia, time to straight leg raise,
complications No losses to follow up described
Unclear (blinding of outcome assessment)
Pre-emptive analgesia with oral Oxycodone and
Celecoxib. Epidural anaesthesia. 90 ml saline
No pre-emptive analgesia No
epidural




















Table 2 Randomised controlled trials of local anaesthetic infiltration in total knee and hip replacement (Continued)
solution containing 5 mg morphine, 40 mg
methylprednisolone and 6.8 mg ropivacaine
infiltrated during surgery. Post-operative oral
Oxycodone and paracetamol.
Post-operative intravenous PCA
and oral and injected analgesics
as required
Liu et al. 2011 [32] China
2008–2009
THR, OA, ASA I–III, <80 years
N = 82 (41:41) 74:74 years
75:77% female
Spinal anaesthesia, PCA morphine 15 days and 9 months (range 6–12 months) for
infection Morphine use, VAS pain, surgical
outcome, mobilisation (time to straight leg
raise and 90 degree flexion) 2 (1:1) lost to
follow up Low risk of bias
60 ml saline solution containing 5 mg morphine,
30 mg bupivacaine, 1 ml betamethasone and
0.5 ml epinephrine infiltrated during surgery.
60 ml saline infiltrated during
surgery.
Lu et al. 2010 [31] China Not
specified
THR, primary N = 40 (20:20) No
information on age and sex of
patients
No description of common anaesthesia except
PCA
48 hours VAS pain, use of PCA pump, adverse
drug reactions No losses to follow up apparent
Unclear (limited reporting)
COX-2 inhibitor before surgery. 100 ml solution
containing 0.15% ropivacaine infiltrated at end of
surgery. COX-2 inhibitor after surgery
No COX-2 inhibitor before
surgery. 100 ml saline placebo
infiltrated at end of surgery.
No COX-2 inhibitor after surgery
Lunn et al. 2011 [33] Denmark
2009–2010
THR, >18 years N = 120 (60:60)
67:67 years 55:65% female
Spinal with or without general. Multimodal oral
analgesia
8 hours and to discharge VAS pain at rest and
during walking and passive hip flexion, Oxycodone
consumption, complications No losses to follow up
except “pain during walking” with 18 (11:7) lost to
follow up Low risk of bias (except pain during
activity: possible risk of bias due to large number
of patients unable to complete test|)
150 ml saline solution containing 0.2%
ropivacaine and 10 μg/ ml epinephrine
infiltrated during surgery.
150 ml saline placebo infiltrated
during surgery.
Murphy et al. 2012 [36] Ireland
2009–2010
THR, OA N = 91 (45:46)
57:54 years 49:38% female
Spinal, PCA opioid analgesia 72 hours WOMAC Pain, McGill Pain Questionnaire,
VAS pain, morphine consumption, complications
13 (6:7) lost to follow up but some analyses used
multi-level modelling to handle missing data Low
risk of bias
60 ml saline containing 150 mg levobupivacaine
infiltrated during surgery.
60 ml saline placebo
Parvataneni et al. Hip 2007
[28] USA 2005–2006
THR, OA N = 71 (35:36)
64:61 years 40:39% female
Spinal anaesthesia with or without FNB 3 months VAS pain, total narcotic dose, functional
recovery including time to straight leg raise, side
effects of narcotic use, patient satisfaction No
losses to follow up reported Low risk of bias
Intra-operative infiltration of 200–400 mg
bupivacaine, 4–10 mg morphine sulphate
300 μg epinephrine, 40 mg methylprednisolone
acetate, 75 mg cefuroxime and 22 ml saline.
Total volume approximately 33 ml.
No infiltration during surgery
Post surgical PCA
Rikalainen-Salmi et al. 2012
[37] Finland 2009–2010
THR, OA, ASA I–III N = 60 (30:30)
65:66 years (followed up) 66:61%
female (followed up)
Spinal, propofol if required, oxycodone rescue
medication.
8 weeks NRS pain at rest and motion, oxycodone
consumption, mobilisation, fulfilment of discharge
criteria, satisfaction, adverse events and
complications 3 (1:2) lost to early follow up. 7 (4:3)
lost to long term follow up Low risk of bias
101 ml solution containing 125 mg
levobupivacaine, 30 mg ketorolac infiltrated
during surgery 21 ml solution containing
100 mg levobupivacaine and 30 mg ketoralac
administered through catheter on morning of
first post-operative day
Intrathecal morphine No placebo
infiltration Sham catheter attached
to skin with 21 ml air administered
on morning of first post-operative
day (not inserted into joint )
TOTAL KNEE REPLACEMENT STUDIES
Affas et al. 2011 [50] Sweden
2007–2008
TKR, 77.5% OA, 22.5% RA, >18 years,
ASA I–III, primary.
N = 40 (20:20) 67:69 years 45:60%
female
Spinal anaesthesia, PCA morphine 24 hours NRS pain intensity at rest and on
movement, 24 hour morphine PCA consumption.
No losses to follow up. Missing data analysis
reported. Unclear risk of bias (blinding of outcome
assessment)
110 ml containing approximately 200 mg
ropivacaine, 20 mg ketorolac and 0.33 mg
epinephrine infiltrated during surgery. Further
intra-articular infiltration through catheter after
surgery.
Femoral nerve block. Intravenous





















Table 2 Randomised controlled trials of local anaesthetic infiltration in total knee and hip replacement (Continued)
Andersen KV et al. 2010 [44]
Denmark 2007–2008
TKR, >18 years N = 49 (24:25)
67:69 years 43:26% female
Spinal anaesthesia, PCA morphine 72 hours and to discharge. Infection to 30 days VAS/
NRS pain, morphine requirement, side effects and
complications, time to achieve discharge criteria,
length of stay, 9 (3:6) patients lost to follow up
Unclear risk of bias (blinding of outcome
assessment)
151.5 ml saline solution containing 300 mg
ropivacaine, 30 mg ketorolac and 0.5 mg
epinephrine infiltrated during surgery. Further
continuous infusion through catheter after
closure.
Epidural infusion of ropivacaine.
Post-operative intravenous
ketorolac
Busch et al. 2006 [38] Canada
Date not specified
TKR, age <80 years N = 64
(32:32) 66:70 years 50:59%
female
General or spinal anaesthesia, PCA morphine 6 weeks VAS at rest and activity, morphine
consumption (PCA), VAS satisfaction, complications,
Knee Society Score, WOMAC, length of hospital stay
No losses to follow up Low risk of bias
100 ml saline solution containing 400 mg
ropivacaine, 30 mg ketorolac, 5 mg
epimorphine, and 0.6 ml epinephrine (1:1000)
infiltrated during surgery.
No placebo infiltration
Carli et al. 2010 [45] Canada
2007–2008
TKR, OA, tricompartmental,
cemented. N = 40 (20:20)
71:71 years 75:70% female
Spinal anaesthesia, PCA morphine 6 weeks Morphine consumption, NRS pain at rest
and walking, functional capacity, ability to walk
30 m, physical activity, SF-12, WOMAC No losses to
follow up Low risk of bias
Solution of ropivacaine (0.2%), 1 ml of ketorolac
(30 mg/ml), and 0.5 ml of epinephrine
(1 mg/ml) with a total volume of 100 ml
infiltrated during surgery. Further infusion
through catheter after closure
Continuous femoral nerve block
Saline injection Post-surgical
infusion of saline
Chen et al. 2012 [52] China
2008
TKR, OA, age <76 years. N = 81
(40:41) 66:65 years 75:78%
female
Spinal anaesthesia, PCA morphine 15 days and infection to 6 months Total morphine
consumption, VAS pain at rest and motion, time to
straight leg raise and 90 degree flexion, adverse
events including delayed infection 1 (0:1) patient
lost to follow up Low risk of bias
Intra-operative injection of a solution of
magnesium sulphate (50 mg/kg) and 190 mg
ropivacaine in normal saline to a volume of
100 ml.
Intra-operative intra-articular
injection of 100 ml normal
saline
Essving et al. 2010 [46]
Sweden 2007–2008
TKR, OA, ASA I–III, 20–85 years
N = 48 (24:24) 72:70 years 54:54%
female
General anaesthesia, PCA morphine 3 months PCA morphine consumption, VAS pain at
rest and on knee flexion, time to home readiness,
length of hospital stay, surgical outcome, functional
outcome tests, Oxford Knee Score, EQ-5D, patient
satisfaction, adverse events 1 (0:1) patient lost to fol-
low up Low risk of bias
116 ml saline containing 300 mg ropivacaine,
30 mg ketorolac and 0.5 mg epinephrine
infiltrated during surgery. 50 ml saline
containing 100 mg ropivacaine infiltrated before
closure. Further injection of mixture 21 h after
closure.
No placebo injections during
surgery. Post-surgical injection
of saline at 21 hours.
Essving et al. 2011 [51]
Sweden 2009–2010
TKR, OA, ASA I–III, age 40–85
years N = 50 (25:25) 71:71 years
64:60% female
Spinal anaesthesia, PCA morphine 3 months VAS pain, PCA morphine, verbal rating
scale of satisfaction, functional tests, time to home
readiness, Oxford Knee Score, EQ-5D, adverse events
2 (0:2) patients lost to follow up Low risk of bias
Spinal plus intrathecal saline. Injection during
surgery of 400 mg ropivacaine (160 ml), 30 mg
ketoralac (1 ml) and 0.5 mg epinephrine (5 ml)
Further infiltrate through catheter on day 1
and 2
Spinal plus intrathecal morphine
No injection during surgery
Post-surgical infusion of saline
through catheter
Fu et al. 2009 [42] China
2006–2007
TKR, OA, age <80y N = 80 (40:40)
69:68 years 75:78% female
Spinal anaesthesia, PCA morphine 15 days except ROM 90 days, infection 12 months
Morphine consumption, VAS pain at rest and
activity, ROM, time to straight leg raise, surgical
outcomes, complications. No losses to follow up.
Missing data imputation described Low risk of bias
60 ml saline containing 5 mg morphine, 30 mg
bupivacaine and 1 ml betamethasone infiltrated
during surgery.
60 ml saline infiltrated during
surgery
Fu et al. 2010 [47] China
2008–2009
TKR, OA, age < 80 years N = 100
(50:50) 68:67 years 76:80%
female
Spinal anaesthesia, PCA morphine 15 days except ROM at 90 days and infection to
mean 7.5 months (range 6–9 months) VAS pain,
morphine consumption (PCA and intramuscular) ,
time to straight leg raise and 90 degree flexion,
surgical outcomes, adverse reactions No losses to
follow up Low risk of bias
Oral COX-2 inhibitor and tramadol 1 day before
to 1 month after surgery 50 ml saline containing
5 mg morphine, 150 mg ropivacaine, 0.5 ml
adrenaline and 1 ml betamethasone infiltrated
during surgery.
Oral placebo 1 day before to






















Table 2 Randomised controlled trials of local anaesthetic infiltration in total knee and hip replacement (Continued)
Han et al. 2007 1 and 2 [40]
Korea 2005–2006 Note: 2
intervention groups
TKR, primary N = (30:30:30)
69:68:67 years 90:80:90% female
Spinal and epidural anaesthesia, PCA morphine 48 hours Incidence of booster PCA for 24 hours,
amount of intra-venous tramadol, VAS pain at rest
and exercising, side effects, range of flexion. No
losses to follow up reported Low risk of bias
1) 50 ml saline solution containing 300 mg
ropivacaine, epinephrine (0.25 ml 1:200,000) and
5 mg morphine injected before wound closure.
2) 50 ml saline solution containing 300 mg
ropivacaine and epinephrine (0.25 ml 1:200,000)
injected before wound closure.
50 ml saline placebo
Koh et al. 2012 [53] Korea
2008–2009
TKR, OA, unilateral N = 101
(49:52) 70:70 years 89:91%
female
FNB, spinal anaesthesia, PCA morphine 7 days VAS pain at rest (day 1) and on movement
(days 4 and 7), PCA opioid consumption, use of
rescue medication, pain compared with
expectations, functional recovery (straight leg raise
and flexion), satisfaction, side-effects and complica-
tions, length of stay. 14 (4:10) did not receive treat-
ment as planned. Results reported by intention to
treat Low risk of bias
50 ml saline containing ropivacaine 300 mg,
morphine sulphate 10 mg, ketoralac 30 mg,
0.3 mg epinephrine, cefuroxime 750 mg
injected/ infiltrated during surgery.
No placebo infiltration reported
Krenzel et al. 2009 [43] USA
2007–2008
TKR, 96% OA elective. N = 67
(35:32), 1 patient with staged
bilateral TKR included twice.
67:65 years 57:72% female
FNB, spinal anaesthesia, PCA fentanyl 24 hours PCA fentanyl consumption, NRS pain,
functional tests, time to straight leg raise,
ambulation distance, surgical outcomes, adverse
events No losses to follow up Low risk of bias
20 ml infiltration of 100 mg ropivacaine
during surgery.
20 ml saline placebo infiltrated
during surgery
Mahadevan et al. 2012 [54]
UK Not specified
TKR, OA or RA, unilateral N = 52
(26:26) 68:67 years 54:58%
female
FNB, general anaesthesia, PCA morphine. 48 hours and to discharge VAS pain, morphine
consumption, active ROM, length of hospital stay.
No losses to follow up reported Low risk of bias25 ml saline containing 0.375% levobupivacaine
infiltrated during surgery.
Sciatic nerve block No placebo
infiltration reported
Meftah et al. 2012 [55] USA
2010–2011
TKR, unilateral N = 90 (45:45)
65:67 years 64:64% female
Pre-emptive analgesia 3 days and to discharge. 6 months for infection,
fracture and re-operation. Pain at rest and ambula-
tion, readiness for discharge.1 (1:0) lost to all follow
up, 6 (4:2) lost to readiness for discharge follow up
Unclear (blinding of outcome assessment)
45.1 ml saline solution containing marcaine
(400–800 mg, morphine sulphate 8 mg,
adrenaline 0.3 mg, antibiotic 750 mg,
corticosteroids 40 mg injected during surgery.
FNB. PCA epiduralNo placebo
injection reported
Ng et al. 2012 [56] China
2008–2010 Note: crossover
design. Patients having both
knees replaced
TKR, OA N = 32 (16:16) surgeries
but 16 patients only having 2
TKRs 3 months apart. 70:70 years
88:88% female
General anaesthesia, remifentanil infusion,
PCA morphine
3 days and to discharge Pain score at rest and
motion, total morphine consumption, Knee Society
Score, ROM, quadriceps power, satisfaction, adverse
events and complications.No losses to follow up
reported Low risk of bias
101.5 ml saline solution containing 300 mg
ropivacaine, adrenaline 1 mg and triamcinolone
acetonide 40 mg infiltrated during surgery.
Femoral catheter inserted and saline infused.
Femoral nerve block. Wound
infiltration with 101.5 ml saline.
Parvataneni et al. Knee 2007
[28] USA 2005–2006
TKR, OA N = 60 (31:29)
69:71 years 45:52% female
Spinal anaesthesia with or without FNB 3 months VAS pain, total narcotic dose, functional
recovery including time to straight leg raise, side
effects of narcotic use, patient satisfaction No losses
to follow up reported Low risk of bias
Intra-operative infiltration of 200–400 mg
bupivacaine, 4–10 mg morphine sulphate
300 μg epinephrine, 40 mg methylprednisolone
acetate, 75 mg cefuroxime and 22 ml saline.
Total volume approximately 33 ml.
No infiltration during surgery
Femoral nerve block at end of
surgery Post surgical PCA Effort
to conceal allocation but no
sham epidural
Spreng et al. no iv injection
2010[48] Norway 2007–2009
TKR, unilateral, non-cemented,
no patella resurfacing, age
>17 years, ASA I–III. N = 68
(34:34) 67:66 years 61:67%
female
Spinal. Propofol if indicated. PCA morphine 72 hours and to discharge VAS at rest and during
knee flexion, morphine consumption, functional
recovery, length of stay, satisfaction, mobilisation
including walking distance, adverse events2 (1:1) lost
to follow up Low risk of bias
150 ml saline solution containing 150 mg
ropivacaine, 0.5 mg epinephrine, 30 mg
ketorolac and 5 mg morphine infiltrated during
surgery. Knee injected through catheter with
ropivacaine and ketorolac solution after
22–24 hours Intravenous injection with saline
at 22–24 hours
48 hours of epidural analgesia
as soon as spinal started to wear
off No wound infiltration during
surgery. No injections through





















Table 2 Randomised controlled trials of local anaesthetic infiltration in total knee and hip replacement (Continued)
Spreng et al. with iv injection
2010 [48] Norway 2007–2009
TKR, unilateral, non-cemented,
no patella resurfacing, age
>17 years, ASA I–III. N = 68
(34:34) 67:66 years 61:67%
female
Spinal anaesthesia, propofol if indicated, PCA
morphine
72 hours and to discharge VAS at rest and during
knee flexion, morphine consumption, functional
recovery, length of stay, satisfaction, mobilisation
including walking distance, adverse events 2 (1:1)
lost to follow up Low risk of bias
150 ml saline solution containing 150 mg
ropivacaine and 0.5 mg epinephrine infiltrated
during surgery. Also intravenous injection of
1 ml ketorolac (30 mg/ml) and 5 ml morphine
(1 mg/ml).Knee injected with saline at 22–24 h
(catheter) Intravenous injection with ketoralac
at 22–24 h
48 hours of epidural analgesia
as soon as spinal anaesthetic
started to wear off. No wound
infiltration during surgery. No
injections through sham catheter
Thorsell et al. 2010 [49] Sweden
Not specified
TKR, OA or RA N = 85 (46:39)
69:72 years (followed up) 81:73%
female (followed up)
Not specified, probable PCA 4 days and to discharge VAS pain, morphine
consumption, satisfaction, mobilisation getting out
of bed without assistance, walking with crutches),
functional recovery, length of hospital stay 21 (13:8)
patients lost to follow up data reported Possible bias
(large uneven losses to follow up, group allocation
by date of birth)
Spinal anaesthesia 156 ml solution with 300 mg
ropivacaine, 0.5 mg adrenaline and 30 mg
ketorolac infiltrated during surgery. Further
infiltrate through catheter intra-articularly on
post-operative day 1.
Spinal or epidural analgesia No
placebo infiltration reported
Post-operative pain relief with
ropivacaine infusion through
epidural catheter.
Toftdahl et al. 2007 [18]
Denmark 2005–2006
TKR, OA with planned spinal
anaesthesia 77 (40:37)
70:72 years 63:60% female
Spinal and after surgery immediate release
oxycodone and intravenous morphine if
required
4 days and to discharge NRS pain, opioid
consumption, mobilisation (able to walk >3 metres,
able to hold quadriceps tension for > 5 sec), length
of hospital stay, adverse events and complications 4
(3:1) patients lost to follow up Unclear (blinding of
outcome assessment)
152 ml solution containing 300 mg ropivacaine,
30 mg ketorolac and 0.5 mg epinephrine
infiltrated during surgery. Further infiltrate through
catheter intra-articularly on day of surgery and
post-operative day 1.
Femoral nerve block prior to




Vendittoli et al. 2006 [39]
Canada 2003–2004
TKR, 95.2% OA N = 42 (22:20)
Ages not specified 73:70%
female
Spinal anaesthesia, PCA morphine 5 days and to discharge VAS pain at rest and during
physiotherapy exercise, PCA morphine consumption,
functional recovery, side effects No losses to follow
up described Low risk of bias
160 ml solution containing in total 400 mg
ropivacaine, 30 mg ketorolac and 0.5 ml
adrenaline (1:1000) infiltrated during surgery.
Infiltrate through catheter intra-articularly on day1.
No placebo infiltration
Zhang et al. 2007 [41] China
2006–2007
TKR, unilateral N = 60 (30:30)
Overall 68 years 83:80% female
PCA morphine 72 hours VAS pain at rest and activity, functional
recovery No losses to follow up described Unclear
(blinding of outcome assessment)60 ml solution containing 0.25% bupivacaine,
epinephrine (1:200,000) and 10 mg morphine
infiltrated during surgery
No placebo injection
TKR: total knee replacement, THR: total hip replacement , OA: osteoarthritis, RA: rheumatoid arthritis, PCA: patient controlled analgesia, FNB: Femoral Nerve Block, VAS: visual analogue scale, NRS: numerical response




















Table 3 Meta-analyses of pain and length of hospital stay by anaesthetic regimen compared with controls using a
random effects model
TOTAL HIP REPLACEMENT STUDIES N Measure Pooled effect size Confidence Interval P-value I2 (%) τ2
(A + B) Any wound infiltration analgesia + usual anaesthesia vs Usual anaesthesia
Pain at rest at 24 h 12 SMD −0.605 ( −1.051, −0.160) 0.0078 89 0.541
Pain during activity at 24 h 9 SMD −0.848 ( −1.450, −0.246) 0.0058 92 0.765
Pain at rest at 48 h 11 SMD −0.285 ( −0.520, −0.050) 0.018 58 0.09
Pain during activity at 48 h 8 SMD −0.432 ( −0.776, −0.089) 0.014 71 0.171
Length of hospital stay 9 MD −0.829 ( −1.540, −0.118) 0.022 84 0.866
(A) Wound infiltration analgesia + usual analgesia vs Usual anaesthesia
Pain at rest 24 h post-op 7 SMD −0.633 ( −1.208, −0.059) 0.031 90 0.529
Pain during activity 24 h post-op 4 SMD −0.241 ( −0.637, 0.155) 0.23 68 0.11
Pain at rest 48 h post-op 6 SMD −0.134 ( −0.348, 0.080) 0.22 19 0.014
Pain during activity 48 h post-op 3 SMD −0.225 ( −0.559, 0.109) 0.19 35 0.03
Length of Hospital Stay 5 MD −0.257 ( −0.622, 0.108) 0.17 14 0.029
(B) Wound infiltration analgesia + post closure analgesia + usual anaesthesia vs Usual anaesthesia
Pain at rest 24 h post-op 5 SMD −0.572 ( −1.383, 0.240) 0.17 90 0.767
Pain during activity 24 h post-op 5 SMD −1.378 ( −2.499, −0.257) 0.016 94 1.525
Pain at rest 48 h post-op 5 SMD −0.489 ( −0.963, −0.015) 0.043 73 0.209
Pain during activity 48 h post-op 5 SMD −0.599 ( −1.158, −0.040) 0.036 80 0.319
Length of Hospital Stay 4 MD −1.117 ( −2.474, 0.239) 0.11 88 1.621
TOTAL KNEE REPLACEMENT STUDIES N Measure Pooled effect size Confidence Interval P-value I2 (%) τ2
(A + B) Any wound infiltration analgesia + usual anaesthesia vs Usual anaesthesia
Pain at rest at 24 h 12 SMD −0.398 ( −0.576, −0.219) p < 0.001 32 0.032
Pain during activity at 24 h 12 SMD −0.453 ( −0.671, −0.235) p < 0.001 54 0.078
Pain at rest at 48 h 12 SMD −0.325 ( −0.546, −0.103) 0.0041 56 0.084
Pain during activity at 48 h 11 SMD −0.273 ( −0.500, −0.046) 0.018 56 0.081
Length of hospital stay 8 MD −0.866 ( −1.622, −0.109) 0.025 77 0.805
(A) Wound infiltration analgesia with no additional post closure analgesia + usual anaesthesia vs Usual anaesthesia
Pain at rest 24 h post-op 6 SMD −0.248 ( −0.452, −0.044) 0.017 14 0.009
Pain during activity 24 h post-op 6 SMD −0.283 ( −0.470, −0.096) 0.0031 0 0
Pain at rest 48 h post-op 6 SMD −0.155 ( −0.458, 0.148) 0.32 61 0.086
Pain during activity 48 h post-op 6 SMD −0.077 ( −0.263, 0.110) 0.42 0 0
Length of Hospital Stay 1 MD 0.092 ( −0.890, 1.073) 0.85 100 p < 0.001
(B) Wound infiltration analgesia + post wound closure analgesia + usual anaesthesia vs Usual anaesthesia
Pain at rest 24 h post-op 6 SMD −0.587 ( −0.829, −0.346) p < 0.001 9 0.008
Pain during activity 24 h post-op 6 SMD −0.693 ( −1.152, −0.234) 0.0031 74 0.24
Pain at rest 48 h post-op 6 SMD −0.52 ( −0.778, −0.262) p < 0.001 21 0.022
Pain during activity 48 h post-op 5 SMD −0.594 ( −0.997, −0.191) 0.0039 61 0.128
Length of Hospital Stay 7 MD −1.023 ( −1.822, −0.224) 0.012 76 0.761
(C) Wound infiltration analgesia + post wound closure analgesia + usual anaesthesia vs Femoral nerve block + usual anaesthesia
Pain at rest 24 h post-op 3 SMD 0.253 ( −0.514, 1.021) 0.52 81 0.37
Pain during activity 24 h post-op 3 SMD 0 ( −0.317, 0.317) 1 0 0
Pain at rest 48 h post-op 2 SMD 0.254 ( −0.429, 0.937) 0.47 67 0.166
Pain during activity 48 h post-op 2 SMD −0.073 ( −0.446, 0.299) 0.7 0 0
Length of Hospital Stay 2 MD 0.07 ( −0.838, 0.978) 0.88 0 0
Marques et al. BMC Musculoskeletal Disorders 2014, 15:220 Page 11 of 20
http://www.biomedcentral.com/1471-2474/15/220
Table 3 Meta-analyses of pain and length of hospital stay by anaesthetic regimen compared with controls using a
random effects model (Continued)
(D) Wound infiltration analgesia + Femoral nerve block + usual analgesia vs Femoral nerve block + usual anaesthesia
Pain at rest 24 h post-op 3 SMD −0.241 ( −0.604, 0.122) 0.19 44 0.046
Pain during activity 24 h post-op 0
Pain at rest 48 h post-op 1 SMD −0.18 ( −0.571, 0.211) 0.37 100 0
Pain during activity 48 h post-op 1 SMD 0.094 ( −0.296, 0.485) 0.64 100 0
Length of Hospital Stay 1 MD 1.52 ( 0.054, 2.986) 0.042 100 0
(E) Wound infiltration analgesia + usual anaesthesia vs Femoral nerve block + usual anaesthesia
Pain at rest 24 h post-op 3 SMD −0.076 ( −0.632, 0.480) 0.79 69 0.166
Pain during activity 24 h post-op 3 SMD 0.159 ( −0.869, 1.187) 0.76 90 0.741
Pain at rest 48 h post-op 2 SMD 0.056 ( −0.300, 0.412) 0.76 0 0
Pain during activity 48 h post-op 2 SMD −0.202 ( −1.034, 0.631) 0.63 75 0.275
Length of Hospital Stay 2 MD −0.069 ( −0.634, 0.497) 0.81 0 0
N: Number of studies in meta-analysis. Two studies (Essving 2011, Parvataneni 2007 hip and knee) reported mean pain scores for the first 48 hours. These data
were duplicated for the 24 and 48 hour outcomes. One study (Andersen LJ, 2007) reported WOMAC pain scores, a composite measure of pain taken at rest and
during activity. These data were duplicated for rest and during activity outcomes.
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ceived additional intrathecal morphine, there was no dif-
ference in pain outcomes at any time point [37].
Heterogeneity measured by the I2 and τ 2 statistics was
high, and separating the analysis for A and B groups didNOTE: Weights are from random effects analysis
.
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Overall  (I−squared = 89.3%, p = 0.000)
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Figure 3 Total hip replacement: pain at rest and during activity by lonot appear to reduce this heterogeneity. Restricting the
analysis to studies with low risk of bias gave a marginally
smaller estimate of reduction in pain at 24 hours at
rest by an average of SMD −0.49 (95% CI −0.89, −0.09;
p = 0.017), but during activity average pain reductionOTE: Weights are from random effects analysis
verall  (I−squared = 91.6%, p = 0.000)
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cal anaesthetic infiltration grouping.
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p = 0.003), corresponding to 28 points on a 100 point
scale.
Opioid consumption
In all 11 studies reporting an outcome, opioid consump-
tion was reduced in patients receiving local anaesthetic in-
filtration compared with controls [10,16,27,30-37]. This
difference ranged from 12 to 92%. There was no sugges-
tion of different effects in groups with or without add-
itional analgesia through a catheter or injection.
In the studies where control patients received epidural
or intrathecal analgesia, patients receiving local anaes-
thetic infiltration consumed 20% and 12% less morphine,
respectively.
Mobilisation
Several different measures of mobilisation were reported.
In three studies patients receiving local anaesthetic infil-
tration with no additional post-operative component
achieved a straight leg raise earlier than control patients
[28,29,32]. More patients were able to walk during the
first post-operative day in two studies where additional
post-operative analgesia was provided through a catheter
[16,37]. In one study with no additional analgesia, withFigure 4 Length of hospital stay by local anaesthetic infiltration grouthe exception of those with adverse events, all patients
were mobilised on the first post-operative day [35]. How-
ever, in patients receiving local anaesthetic infiltration,
walking speed over six metres at a two-day functional
assessment was improved.
In one study, 35% of patients receiving local anaesthetic
infiltration were able to walk after 8 hours compared with
87% of control patients receiving an epidural infusion. In
the study where control patients received intrathecal mor-
phine, 33% of these patients could walk further than 5 me-
tres on the first post-operative day compared with 71% of
patients receiving local anaesthetic infiltration.
Length of hospital stay
As shown in Table 3 and Figure 4, patients receiving
local anaesthetic infiltration spent an average 0.83 fewer
days (95% CI 0.12, 1.54 days; p = 0.022) in hospital com-
pared with controls. Benefit was largely driven by inter-
ventions with additional analgesia through a catheter or
injection (B comparisons). Heterogeneity across studies
was high (I2 = 84%), mainly in studies with additional
post-operative analgesia.
When the comparison group received an epidural in-
fusion [16], patients with local anaesthetic infiltration
had on average a two day shorter hospital stay. In theping.
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morphine [37], there was no clear difference in discharge
times.
Complications
The Peto OR for a major complication in patients with
local anaesthetic infiltration compared with controls was
0.30 (95% CI 0.05, 1.77; p = 0.18), but this is weak evi-
dence, based on five major complications in 896 pa-
tients. Five deep infections were reported, four in local
anaesthetic infiltration patients and one in controls, Peto
OR 3.47 (95% CI 0.58, 20.81; p = 0.17). Four infections
occurred in the 218 patients who received post-closure
delivery of infiltrate through a catheter.
The incidence of vomiting was reduced in patients re-
ceiving local anaesthetic infiltration in five studies with
309 patients with data, Peto OR 0.46 (95% CI 0.27, 0.80;
p = 0.006).
Long-term outcomes
Five studies reported long-term outcomes. Andersen
and colleagues reported a trend for improved Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) pain scores at six weeks in local anaesthetic
infiltration patients compared with controls [27]. At
eight week follow up, Rikalainen-Salmi and colleagues
reported no differences in mobilisation, intensity or dur-
ation of pain [37]. Parvataneni and colleagues reported
that VAS pain scores were “comparable between groups”
at 3 months [28]. Similarly, Aguirre and colleagues re-
ported no difference in analgesic consumption or pain
during normal daily activities between groups at 3 months
[34]. Busch and colleagues reported a trend for improved
WOMAC score at two years in local anaesthetic infiltra-
tion patients compared with controls [30].
Total knee replacement
Overall there were 23 studies including 1,439 patients
with TKR [18,28,38-56]. Study characteristics and our
overall risk of bias assessment are summarised in Table 2.
The mean number of patients randomised was 63 (range
32–101). We assessed that 17 studies were at low risk of
bias and that five studies had unclear risk of bias based
on uncertainty about blinding of outcome assessments.
One study was assessed to be at high risk of bias due to
a large uneven loss to follow up between randomised
groups.
Pain
As shown in Table 3 and Figure 5, there was strong evidence
that on average across 12 studies [39-42,44,46-48,51,52], pa-
tients receiving local anaesthetic infiltration (A + B studies)
reported lower pain at rest compared with controls at 24
and 48 hours. For example, pain at rest at 24 hours andduring activity at 48 hours was reduced by SMD −0.40
(95% CI −0.58, −0.22; p < 0.001) and SMD −0.27 (95%
CI −0.50, −0.05; p = 0.018), respectively. This reflected
reductions in pain at rest at 24 hours by an average of
10 points (95% CI 6, 15; p < 0.001) and during activity
at 48 hours by 8 points (95% CI 1.5, 15; p = 0.018) on a
100 point scale.
Heterogeneity was moderate to low. When we re-
stricted analyses to studies assessed as low risk of bias,
pain outcome estimates were slightly attenuated towards
zero.
We additionally performed separate analyses according
to whether additional analgesia was delivered after
wound closure through a catheter or injection. In the
six studies with no further analgesia (A studies)
[40-42,47,52], pain at 24 hours was lower at rest by
SMD −0.25 (95% CI −0.45, −0.04; p = 0.017), and during
activity by SMD −0.28 (95% CI −0.47, −0.10; p = 0.003). At
48 hours, pooled effect estimates favoured local anaes-
thetic infiltration but there was no strong evidence that
the intervention was beneficial.
In six studies with additional analgesia delivered after
wound closure (B studies) [39,44,46,48,51], pain was re-
duced on average at 24 hours at rest by SMD −0.59
(95% CI −0.83, −0.35; p < 0.001) and during activity
by SMD −0.69 (95% CI −1.15, −0.23; p = 0.003). At
48 hours, pain was reduced at rest by SMD −0.52
(95% CI −0.78, −0.26; p < 0.001) and during activity by
SMD −0.59 (95% CI −1.00, −0.19; p = 0.004).
In six studies comparing local anaesthetic infiltration
with or without additional post-closure analgesia against
femoral nerve block, there was no evidence for improve-
ment in pain at any time point [18,28,45,50,55,56]. In
three studies where both randomised groups received a
femoral nerve block (D studies) [43,53,54], there was no
evidence for added benefit of local anaesthetic infiltra-
tion for pain outcomes.
In eight comparisons between local anaesthetic infil-
tration with controls [38,39,44,46,48,49,51], additional
ketoralac was included in the wound infiltrate. In seven
comparisons with data [38,39,44,46,48,51], there was
strong evidence that patients receiving additional anal-
gesia in the infiltrate on average had lower pain com-
pared with controls. For example, pain was reduced on
average at rest at 24 hours by SMD −0.68 (95% CI
−0.94, −0.42; p < 0.001) and during activity at 48 hours
by SMD −0.59 (95% CI −1.01, −0.17; p = 0.006), equiva-
lent to a reduction of 17 and 30 points respectively on a
100 point scale.
In four studies, control patients received either an epi-
dural infusion [44,48,49] or intrathecal morphine [51].
Results of all studies supported a reduction in pain for
patients receiving local anaesthetic infiltration compared
with epidural or intrathecal morphine.
Figure 5 Total knee replacement: pain at rest and during activity by local anaesthetic infiltration grouping.
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In all four studies reporting opioid consumption, this was
reduced by 35–40% in patients receiving wound infiltrationwith no additional post-closure analgesia [38,42,47,52], and
by 32–52% in three studies with additional post-closure
analgesia, compared with controls [39,46,51].
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received femoral nerve block, there was little difference
in opioid consumption between randomised groups
[18,28,43,45,50,53].
In four studies where patients receiving wound infil-
tration with further post-closure analgesia were com-
pared with patients receiving epidural anaesthesia, there
was no consistent difference between groups [44,48,49].
Mobilisation
Nineteen studies reported a mobilisation outcome. In
four studies, patients receiving local anaesthetic infiltra-
tion had reduced time to achieve a straight leg raise by
an estimated 44–50% [42,47,52] or were more likely to
achieve a straight leg raise on the first post-operative day
compared with control patients [28]. In two studies with
femoral nerve block given to all patients, more patients
receiving local anaesthetic infiltration were able to
achieve a straight leg raise during the first post-operative
day [43,53].
In four out of five studies, patients receiving local anaes-
thetic infiltration achieved better knee flexion [39,40,47,54].
In four studies [44,46,51,55], ambulation was part of dis-
charge readiness criteria. These criteria were met earlier in
local anaesthetic infiltration patients in three studies
[44,46,51], but were similar in one study where control
patients received a femoral nerve block [55].
Improvements to diverse walking goals were reported
in patients receiving local anaesthetic infiltration in three
studies where some or all of the comparison group pa-
tients received epidural analgesia [48,49]. When the
comparison group or all patients received femoral nerve
block, walking goals were achieved earlier after local an-
aesthetic infiltration in one study [18], with trends for
benefit in two studies [43,45].
Length of hospital stay
Data on length of hospital stay were available for 8 stud-
ies comparing local anaesthetic infiltration with controls
[38,39,44,46,48,49,51], of which seven had a post-closure
analgesia component. As shown in Table 3 and Figure 4,
length of hospital stay was reduced in patients receiving
local anaesthetic infiltration and additional post-closure
delivery (B studies) by 1.0 day on average (95% CI 0.2,
1.8 days; p = 0.012) compared with controls. In the one
(A) study with no post-closure analgesia component
there was no difference in length of hospital stay.
In three studies where the comparison group received
femoral nerve block [18,45,55], there was no suggestion
of a difference in length of stay. In one study in which
all randomised patients received a femoral nerve block,
the length of hospital stay was about 1.5 days shorter in
the control patients who also received a sciatic nerve
block [54].In four studies where the control group received epi-
dural analgesia [44,48,49], length of hospital stay was re-
duced in patients receiving local anaesthetic infiltration
with the exception of one study in which the authors re-
ported shorter time to fulfilment of discharge criteria [44].
Complications
Based on 11 events, the Peto OR for a major complication
was 1.17 (95% CI 0.35, 3.86; p = 0.80) in patients receiving
local anaesthetic infiltration compared with controls. There
were two deep infections in intervention patients [18,44],
and one in control groups [48], Peto OR 1.85 (95% CI 0.19,
17.83; p = 0.59). Two infections occurred in the 287 pa-
tients who received post-closure delivery of infiltrate
through a catheter.
Excluding one intervention with additional morphine
[40], there was evidence that the incidence of vomiting
was lower in local anaesthetic infiltration patients com-
pared with controls in eight studies with 548 patients
[40,42,46-48,51,52], Peto OR 0.56 (95% CI 0.39, 0.80;
p = 0.002).
Long-term outcomes
Five studies reported outcomes measured at six weeks
[38,45], or three months [28,46,51]. Busch and colleagues
showed a trend for improved pain at 6 weeks favouring
the intervention group [38]. Parvataneni and colleagues
reported comparable pain scores between groups at
3 months [28]. In the studies of Essving and colleagues,
there were no differences between median Oxford Knee
Scores at 3 months [46,51].
Carli and colleagues reported poorer WOMAC scores
after 6 weeks in patients receiving local anaesthetic infil-
tration compared with the control group who received
femoral nerve block [45].
Discussion
Our systematic review and meta-analyses represent a
comprehensive overview of evaluations of the effective-
ness of peri-operative local anaesthetic infiltration in
THR and TKR. Systematic reviews allow for a more ob-
jective appraisal than traditional narrative reviews [57],
which are often biased in their selection of studies and
thus may be unreliable in their recommendations of in-
terventions [58]. Extensive efforts to acquire information
from authors on unpublished outcomes and variance
data allowed us to apply methods for meta-analyses of
continuous and skewed outcomes and to produce more
robust results for some outcomes than could be achieved
with a purely narrative synthesis.
In conducting this systematic review we recognised
the problems that can arise when small studies are in-
cluded in meta-analyses [59]. In this review it is note-
worthy that 28 out of 35 studies (80%) reported a power
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in highly controlled conditions in the peri-operative and
early post-operative period benefitted from low losses to
follow up and more complete data. With the exception
of one study where the authors acknowledged uneven
losses to follow up due to inadequate protocols, the
main risk of bias arose from uncertainty about blind out-
come assessment. As most studies reported VAS pain
and other self-reported outcomes, we believe that the
evidence base on short-term outcomes is of reasonably
good quality.
Pain after THR was reduced for patients receiving
local anaesthetic infiltration, with patients experiencing
less pain at rest at 24 hours and during activity at
48 hours equivalent to about 12 and 10 points on a 100
point pain intensity scale. In musculoskeletal settings,
VAS pain changes of 11 [60], and 14 [61], are considered
clinically significant [62]. Patients receiving local anaes-
thetic infiltration had lower pain levels after their THR,
used less opioid medication and had a reduced incidence
of vomiting and nausea. This may explain the early mo-
bilisation and earlier discharge of patients who received
local anaesthetic infiltration, irrespective of alternative
pain management strategies. Opioid medication is a key
strategy in the management of post-surgical pain but its
use can delay mobilisation and rehabilitation [63].
Pain after TKR was also reduced for patients receiving
local anaesthetic infiltration compared with controls,
with less pain at rest at 24 hours and after 48 hours dur-
ing activity, equivalent to reductions of about 10 and 8
points on a 100 point pain intensity scale. Opioid con-
sumption was reduced compared with untreated control
patients and there was a general observation of early
mobilisation, reduced vomiting and nausea, and early
hospital discharge. Inclusion of the non-steroidal anti-
inflammatory agent ketoralac in the infiltrate seemed to
enhance post-operative pain relief.
When compared with alternative regimens, results
were not so clear. Pain levels after TKR were broadly
similar when femoral nerve block was included in the
general analgesia regimen or as a comparator. Likewise,
opioid consumption was similar. There was some sug-
gestion of benefit for earlier mobilisation, but length of
hospital stay was not reduced in patients receiving local
anaesthetic infiltration. Femoral nerve block is a well
established method of providing analgesia after TKR and
is associated with reduced opioid requirement and thus
fewer side effects such as nausea and vomiting. However,
femoral nerve block is associated with decreased quadri-
ceps function for a time and an increased risk of falls
[64,65].
In studies in patients receiving TKR where control
groups received epidural or intrathecal analgesia, benefit
was observed for reduced pain in patients receiving localanaesthetic infiltration. Opioid consumption did not dif-
fer between groups but mobilisation and hospital dis-
charge were achieved earlier in patients receiving local
anaesthetic infiltration.
The improvement in pain control and shorter hospital
stay was greatest for patients receiving additional anal-
gesia through a catheter or by injection. However, we
observed a small but potentially important increase in
rates of serious infection, particularly in patients receiv-
ing further infiltrate through a catheter post-wound
closure. Across THR and TKR studies, there were eight
cases of deep infection requiring surgical debridement
or revision. Six of these were in patients randomised to
wound infiltration analgesia with additional analgesia
through a post-surgical catheter. Indeed, all patients with
deep infection had been randomised to receiving a cath-
eter although researchers reported that catheters in con-
trol groups were not inserted into the joint capsule. The
overall rate of infection in patients with THR or TKR
randomised into wound infiltration analgesia studies was
0.34% and in patients receiving an active catheter the
rate was 1.4%.
Few studies in patients with THR or TKR reported
long-term follow up of patients and results were equivo-
cal. Acute post-operative pain is an important risk factor
for long-term pain [66,67], and deserves appropriate
consideration in future studies of peri-operative pain
control.
Our study has limitations. Although meta-analyses per-
formed were enhanced by extensive contact with authors,
imputation was required for some measures of variability.
The skewed nature of hospital stay required transform-
ation under assumptions of a lognormal distribution [26].
For opioid consumption and mobilization there was insuf-
ficient consistency in measures reported to conduct any-
thing but a systematic narrative overview. We noted a
range of analgesia regimens, with different studies making
different comparisons, particularly for TKR. We consid-
ered it unnecessary to make indirect comparisons between
regimens, since direct evidence was available for all the
comparisons of interest.
A further limitation of meta-analyses in a highly active
field of research such as wound infiltration analgesia is
that they may become out of date quickly. Their value is
emphasised, however, in a widely cited example when
studies of streptokinase in acute coronary heart disease
were conducted long after a critical mass of evidence
had been obtained from meta-analysis showing benefit
for patients [68]. Prior to submission, we updated
searches in December 2013 and identified 12 new stud-
ies, three in patients with THR and nine in patients with
TKR. Our results for local anaesthetic infiltration in pa-
tients receiving THR were supported with reduced pain
compared with untreated control [69-71], or similar pain
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our meta-analyses in patients receiving TKR were also
supported with improved early pain control in patients
receiving local anaesthetic infiltration [72]; further pain
reduction with added ketoralac [73,74] but not steroid
[75]; and uncertainty when compared with femoral
nerve block [76-80].
Our results show that local anaesthetic infiltration is
effective in reducing short-term pain after THR and
TKR when compared with no anaesthetic infiltration.
The effect of local anaesthetic infiltration is enhanced
with the addition of post-closure analgesia, although this
needs to be considered in light of the infection risks as-
sociated with catheters [81]. In TKR, there may be no
added benefit to femoral nerve block. Further studies are
in progress to assess long-term effectiveness of local an-
aesthetic infiltration [11].
Conclusions
Our systematic review and meta-analysis shows that
inclusion of local anaesthetic infiltration in a multi-
modal anaesthesia regimen is effective in reducing short-
term pain and hospital stay in patients receiving THR and
TKR. Enhanced pain control was observed when add-
itional analgesia was provided after wound closure
through a catheter but benefit should be weighed
against a possible infection risk. For patients with
TKR, inclusion of the non-steroidal anti-inflammatory
agent ketoralac in the infiltrate seemed to enhance pain
relief. There was no evidence of pain control additional to
that provided by femoral nerve block in patients receiving
TKR. Few studies reported long-term outcomes and fu-
ture research should assess whether local anaesthetic
infiltration can affect the development of long-term
post-surgical pain.
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